Targeting Phosphatidylcholine-Specific Phospholipase C for Atherogenesis Therapy
Atherosclerosis, a dynamic and progressive vascular disease arising from the combination of endothelial dysfunction and inflammation, is becoming a major killer in the 21st century. Accumulating evidence implicates phosphatidylcholine-specific phospholipase C (PC-PLC) in endothelial dysfunction and several inflammation processes. In addition, in a recent study, we demonstrated that PC-PLC contributed to the progression of atherosclerosis. Considering the important roles of PC-PLC in vascular endothelial cell dysfunction and its proinflammatory properties, we propose that a pharmacological blockade of PC-PLC represents a rational approach to atherosclerosis therapy.
Li, Hai Y.; Zhang, Lu; Yin, De L.; Zhang, Yun; and Miao, Jun Y.. 2010. Targeting Phosphatidylcholine-Specific Phospholipase C for Atherogenesis Therapy. Trends in Cardiovascular Medicine. Vol.20(5). 172-176. https://doi.org/10.1016/j.tcm.2011.02.002 PMID: 21742273 ISSN: 1050-1738